Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279892 | 0.88 | LMNA (0.59) | CYP3A4CYP2C9MEN1KMT2AGAA | |
| SCHEMBL5467045 | 0.85 | DDX3X (0.69) | DDX3XCYP3A4CYP2C9RECQLMEN1 | |
| SCHEMBL3983832 | 0.84 | HPGD (0.65) | DDX3XCYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL5468786 | 0.81 | ALDH1A1 (0.71) | DDX3XMEN1KMT2AMAPTLMNA | |
| SCHEMBL26931604 | 0.81 | GUSB (0.63) | CYP3A4CYP2C9MEN1KMT2AGAA | |
| SCHEMBL13011714 | 0.80 | KMT2A (0.74) | CYP3A4CYP2C9MEN1KMT2AGAA | |
| SCHEMBL23200347 | 0.80 | KEAP1 (0.65) | MEN1KMT2AGAALMNAMAPK1 | |
| SCHEMBL5467385 | 0.80 | DDX3X (0.71) | DDX3XMEN1KMT2AMAPTLMNA | |
| SCHEMBL11863940 | 0.80 | DDX3X (1.00) | DDX3XCYP3A4CYP2C9RECQLMEN1 | |
| SCHEMBL7373349 | 0.79 | KMT2A (0.68) | CYP3A4CYP2C9MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20180333376-A1 | USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2018-11-22 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | DDX3X 3247/4885CYP3A4 1715/4885CYP2C9 2416/4885 |
| US-20180333376-A1 | USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | COL1A1, COL2A1, COL14A1 | DDX3X 1763/4885CYP3A4 1098/4885CYP2C9 773/4885 |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | COL1A1, COL2A1, COL14A1 | DDX3X 1763/4885CYP3A4 1098/4885CYP2C9 773/4885 |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | COL1A1, COL2A1, COL14A1 | DDX3X 1763/4885CYP3A4 1098/4885CYP2C9 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.